News zum Sektor Gesundheit aus China

 

ExxonMobil, Eli Lilly, Johnson & Johnson, and Sinopec headline a two-day program where petrochemicals, pharma, and the energy transition converge HOUSTON, June 3, 2026 /PRNewswire/ -- ChemE Show 2026 Powered by ACHEMA opens June 9-10 at the George R. Brown Convention Center in Houston,......

Citi published a research report noting that bipartisan US lawmakers proposed a bill on June 2 to include US outbound investment in Chinas biotechnology sector under the review requirements of the Comprehensive Outbound Investment National Security Act (COINS Act). The proposed legislation, titled the National Security Biotechno......

GenScript Biotech Holdings surged in Hong Kong after the Chinese biotechnology company pushed back against renewed scrutiny from US lawmakers over alleged national security concerns. The shares rose as much as 29 per cent on Wednesday before trimming gains to trade 18 per cent higher at HK$14.35 by late morning. The benchmark Hang Seng Index fell 1.6 per cent. The Nanjing-based company issued a statement saying it operated transparently and professionally across all markets and adhered to the......

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for......

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety....

SHANGHAI, June 2, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the CDP Supplier Engagement Assessment (SEA) A List for the second consecutive year. The......

GENSCRIPT BIO (01548.HK) opened 14.99% higher today and once reached a peak of HKD15.6. It last stood at HKD14.48, up 19.28%, with a turnover of 29.861 million shares, involving HKD437 million.Legend Biotech Corporation (LEGN.US), an associate of the Company, announced that promising preliminary clinical data for LB2501, its inv......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June:...

Joby Aviation, Curaleaf Holdings, and Pony AI may not be the safest stocks to own, but they possess some attractive upside in the future....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

The Hong Kong government's planned offshore yuan-denominated venture capital fund is set to attract investors looking to invest in a wide range of artificial intelligence, biotechnology and new energy firms in the coming years, according to industry players. Financial Secretary Paul Chan Mo-po said on Monday that Hong Kong Investment Corporation (HKIC), the government's investment arm which manages a HK$62 billion (US$8 billion) portfolio, will take the lead in setting up an offshore......

There was HKD950.8 million, HKD344.4 million and HKD32 million Southbound Trading net inflow to SMIC (00981.HK), AKESO (09926.HK) and BABA-W (09988.HK).There was HKD2.1 billion, HKD916.6 million and HKD716.4 million Southbound Trading net outflow from TENCENT (00700.HK), XIAOMI-W (01810.HK) and MEITUAN-W (03690.HK).For Southboun......

WUXI APPTEC (02359.HK) repurchased 1.0324 million ordinary shares of the company on the Stock Exchange of Hong Kong today (2nd) at prices ranging from HKD122.6 to HKD130.2 per share, involving approximately HKD155 million.Since the approval of the share repurchase mandate on 28 April 2026, the company has cumulatively repurchase......

China SXT Pharmaceuticals shares rose 25.6% after hours after announcing an ATM equity offering of up to $100 million via Univest Securities. Importance Rank:  1 read more...

BofAS issued a report stating that AKESO (09926.HK) presented the overall survival analysis of the HARMONi-6 study at the oral Plenary Session of ASCO 2026. This marks the first time in ASCOs 61-year history that an innovative oncology drug originally developed in China has been selected for the Plenary Session.Given the strong ......

LIVZON PHARMA (01513.HK) announced that its controlling subsidiary Livzon Mabpharm has received a "Notice of Acceptance" issued by the National Medical Products Administration. The domestic production drug registration and marketing authorization application for "Laikang Qita Monoclonal Antibody Injection", jointly developed by ......

ALPHAMAB-B (09966.HK) announced that the latest results from the Phase I clinical study (Study No.: JSKN016-101) of JSKN016, an antibody-drug conjugate (ADC) targeting TROP2 and HER3, for the treatment of HER2- locally advanced or metastatic breast cancer (BC), were presented during the poster session at the 2026 ASCO Annual Mee......

Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

Bristol Myers Squibb CEO Chris Boerner sits down with CNBC's Angelica Peebles at the American Society of Clinical Oncology's annual meeting to discuss the company's latest cancer drug data, its $15 billion deal with China's Hengrui, and more....